KeraVet Bio Revenue and Competitors
Estimated Revenue & Valuation
- KeraVet Bio's estimated annual revenue is currently $1.2M per year.
- KeraVet Bio's estimated revenue per employee is $77,500
Employee Data
- KeraVet Bio has 15 Employees.
- KeraVet Bio grew their employee count by 36% last year.
KeraVet Bio's People
Name | Title | Email/Phone |
---|---|---|
1 | Director Marketing | Reveal Email/Phone |
KeraVet Bio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $11.2M | 72 | -13% | N/A | N/A |
#2 | $5099.8M | 32902 | -4% | N/A | N/A |
#3 | $1.7M | 11 | 0% | N/A | N/A |
#4 | $0.6M | 4 | -56% | N/A | N/A |
#5 | $0.9M | 11 | -39% | N/A | N/A |
#6 | $1.7M | 11 | 10% | N/A | N/A |
#7 | $0.6M | 4 | -33% | N/A | N/A |
#8 | $4.8M | 31 | -6% | N/A | N/A |
#9 | $6.4M | 41 | 3% | N/A | N/A |
#10 | $4.2M | 27 | -18% | N/A | N/A |
What Is KeraVet Bio?
At KeraVet® Bio we love our pets, which is why we have created KeraVet Gel to revolutionize animal wound care. KeraVet Gel is a reformulation of an FDA-cleared product used in human clinics called KeraStat® Gel and is based on our leading science and patent-protected technology. KeraVet Gel is indicated for managing common wounds in dogs and cats, including hotspots, lick granulomas, and surgical incisions. KeraVet Gel is applied topically and is designed to lessen healing time and reduce or eliminate the need to keep your pet in an e-collar. The team at KeraVet Bio has decades of experience in medical research and commercialization of wound and regenerative medicine products. From medicine to consumer healthcare, our team brings a wealth of knowledge and experience in creating, testing, and manufacturing FDA-regulated products.
keywords:N/AN/A
Total Funding
15
Number of Employees
$1.2M
Revenue (est)
36%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.5M | 17 | 13% | N/A |
#2 | $1.5M | 17 | 6% | N/A |
#3 | $2.7M | 18 | -49% | N/A |
#4 | N/A | 18 | -38% | N/A |
#5 | $2.8M | 20 | 0% | N/A |